CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Landmark clinical trial reports 33% prostate cancer survival benefit from novel hormone therapy
Presented at ASCO 2019 the landmark ENZAMET | CCTG PR17 (NCT02446405) clinical trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer. Findings, show that men with this sort of cancer who receive enzalutamide with standard treatment have a 33% improvement in survival compared to men receiving standard treatment alone.
“The benefits of enzalutamide had already been established for prostate cancers that are no longer responding to hormonal therapy,” said ENZAMET study co-chair, Professor Ian Davis from the lead group the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). “The actual result in patients starting hormonal therapy noted that patients had a 60% improvement in the time it takes to detect the cancer growing again along with a 33% increase chance of survival was far higher than we expected.”
“This data represents an important advance in our knowledge of how to treat this stage of prostate cancer and we look forward to longer term follow-up data on survival and treatment side effects as well as quality of life,” says CCTG Senior Investigator Dr. Wendy Parulekar.
More >>
Canadian Cancer Trials Group awarded $25 million in funding to support clinical trials
The CCTG has been awarded more than $25 million CAD from the U.S. National Institutes of Health and National Cancer Institute.
More >>
Innovative study advances personalized medicine for prostate cancer patients
CCTG IND224 is a new clinical trial, opening across Canada, is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world.
More >>
Strength in Numbers
Patients facing a cancer diagnosis invariably have many questions, but one tops the list – what is the best treatment? Answering that question is the compelling goal of medical research that is testing new treatments for similarly-diagnosed patients in carefully monitored and controlled ways.
More >>
Innovative study advances personalized medicine for prostate cancer patients
CCTG IND224 is a new clinical trial, opening across Canada, is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world.
More >>
CCTG LY16 | RELEVANCE published in New England Journal of Medicine
The results of the CCTG LY16 trial of Rituxmab plus Lenalidomide in Advanced Untreated Follicular Lymphoma (RELEVANCE), recently published in New England Journal of Medicine, has the potential to offer a new treatment option to lymphoma patients, that does not require chemotherapy.
More >>
The rise of precision medicine
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
More >>Planned trials
CRC9
Circulating Tumor DNA as a Predictive Marker for Response to Chemotherapy in Pts with Stage II Colon Ca
Recently activated
The rise of precision medicine
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
More >>
TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancer
Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.
More >>
Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide
Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.
More >>
Canadian Cancer Research Alliance announces award winners
Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham will receive the Exceptional Leadership in Patient Involvement in Cancer award.
More >>Publications
Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo).
J Clin Oncol 37, 2019
Olson D;Bao R;Allred JB;Strand C;Zha Y;Carll TC;Labadie B;Bastos BR;Butler MO;Munster PN;Schwartz GK;Luke JJ;
United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-a2b for resected high-risk melanoma.
J Clin Oncol 37, 2019
Tarhini AA;Lee SJ;Hodi FS;Rao UNM;Cohen GI;Hamid O;Hutchins LF;Sosman JA;Kluger HM;Sondak VK;Koon HB;Lawrence DP;Kendra KL;Minor DR;Lee CB;Albertini MR;Flaherty LE;Petrella TM;Kirkwood JM;
PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).
J Clin Oncol 37, 2019
Harshman LC;Puligandla M;Haas NB;Allaf M;Drake CG;McDermott DF;Signoretti S;Cella D;Gupta RT;Shuch BM;Choueiri TK;Lara P;Kapoor A;Heng DYC;Jewett MAS;Master VA;Michaelson MD;Leibovich BC;Maskens D;Carducci MA;
Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.
J Clin Oncol 37, 2019
Sparano JA;Gray RJ;Makower DF;Lively TG;Saphner TJ;Keane MM;Gomez HL;Reddy PS;Goggins TF;Mayer IA;Toppmeyer D;Brufsky A;Goetz MP;Hayes DF;Dees EC;Pritchard KI;Geyer CE;Olson JA;Albain KS;Sledge GW;
CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).
J Clin Oncol 37, 2019
Chen EX;Jonker DJ;Loree JM;Kennecke HF;Berry SR;Couture F;Ahmad CE;Goffin JR;Kavan P;Harb M;Colwell B;Samimi S;Samson B;Abbas T;Aucoin N;Aubin F;Koski SL;Wei AC;Tu D;O'Callaghan CJ;
Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.
J Clin Oncol 37, 2019
Sweeney C;Martin AJ;Zielinski RR;Thomson A;Tan TH;Sandhu SK;Reaume MN;Pook DW;Parnis F;North SA;McDermott R;McCaffrey J;Marx GM;Lawrence NJ;Horvath L;Frydenberg M;Chowdhury S;Chi KN;Stockler MR;Davis ID;
Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC)(Alliance A021202).
J Clin Oncol 37, 2019
Bergsland EK;Mahoney MR;Asmis TR;Hall N;Kumthekar P;Maitland ML;Niedzwiecki D;Nixon AB;O'Reilly EM;Schwartz LH;Strosberg JR;Meyerhardt JA;
Cctg MA.39 tailor RT: A randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693).
J Clin Oncol 37, 2019
Parulekar WR;Berrang T;Kong I;Rakovitch E;Theberge V;Gelmon KA;Chia SKL;Bellon JR;Jagsi R;Ho AY;White JR;Zellars RC;Bane A;Boileau J;Lemieux J;Montenegro A;Chen BE;Whelan TJ;